324737-10-2

Basic information

• Product Name: Methyl 2-Methyl-3-oxo-3-(pyrazin-2-yl)propanoate
• Synonyms: Methyl 2-Methyl-3-oxo-3-(pyrazin-2-yl)propanoate;Methyl 2-Methyl-3-oxo-3-(2-pyrazinyl)propanoate;2-Methyl-3-oxo-3-pyrazin-2-yl-propionic acid methyl ester;2-Methyl-3-(pyrazin-2yl-3-oxoproplonate
• CAS NO: 324737-10-2
• Molecular Formula: C₉H₁₀N₂O₃
• Molecular Weight: 194.1873
• EINECS: 200-589-5
• Mol File: 324737-10-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 2-Methyl-3-oxo-3-(pyrazin-2-yl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-Methyl-3-oxo-3-(pyrazin-2-yl)propanoate(324737-10-2)
• EPA Substance Registry System: Methyl 2-Methyl-3-oxo-3-(pyrazin-2-yl)propanoate(324737-10-2)

Safety Data

• Hazardous Substances Data: 324737-10-2(Hazardous Substances Data)

Usage

General Description

Methyl 2-Methyl-3-oxo-3-(pyrazin-2-yl)propanoate is a chemical compound consisting of a methyl group, a 2-methyl-3-oxo-3-(pyrazin-2-yl)propanoate group. Methyl 2-Methyl-3-oxo-3-(pyrazin-2-yl)propanoate is often used in pharmaceutical and chemical research as a building block for the synthesis of various drugs and chemicals. It possesses a pyrazine ring structure which gives it potential biological activity, making it a valuable molecule for drug discovery and development. Its structure and properties make it a versatile and valuable chemical for use in various applications within the pharmaceutical and chemical industries.

Upstream product

• 98-97-5 2-pyrazylcarboxylic acid 
• 554-12-1 propanoic acid methyl ester 
• 6924-68-1 ethyl 2-pyrazinecarboxylate 
• 6164-79-0 methyl pyrazine-2-carboxylate 

Downstream Products

• 64224-21-1 Oltipraz 

Relevant articles and documents

Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor

Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor which is strongly associated with tumor survival, progression, and therapeutic resistance. Accordingly, it has been suggested that the inhibition of the HIF-1 pathway can suppress tumor, and it has become an important therapeutic target. In present study, oltipraz, its metabolite M2, and their derivatives were synthesized and evaluated as HIF-1α inhibitors. Among the synthesized, benzyl-substituted pyrrolo[1,2-a]pyrazine 2g most potently inhibited HIF-1α protein accumulation (81% at 10 μM) and VEGF, GLUT-1 transcription (77% and 92% at 10 μM, respectively).

Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement

The invention provides methods to treat neurological disorders such as Alzheimer's disease, or to slow the progression of such diseases, or to treat and/or prevent other disorders as disclosed in the specification, by administering to patients, or delivering to the tissues of such patients, oltipraz or related compounds as disclosed in the specification.

Structural determinants for AMPA agonist activity of aryl or heteroaryl substituted AMPA analogues. Synthesis and pharmacology

We have previously reported the synthesis and pharmacological characterization of analogues of 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA, 1a), in which the methyl group was replaced by a phenyl group (APPA, 1b) or heteroaryl groups. While 2b and its 3-pyridyl analogue 2-amino-3-[3-hydroxy-5-(3-pyridyl)-4-isoxazolyl]propionic acid (3-Py-AMPA, 3) show very low affinity for AMPA receptors, introduction of heteroaryl substituents containing heteroatom in the 2-position provides potent AMPA receptor agonists. We here report the synthesis and pharmacology of 2-amino-3-(3-hydroxy-5-pyrazinyl-4-isoxazolyl)propionic acid (7) (IC50 = 1.2 μM; EC50 = 11 μM), which is weaker as an AMPA agonist than AMPA (IC50 = 0.040 μM; EC50 = 3.5 μM) but comparable in potency with 2-Py-AMPA (4) (IC50 = 0.57 μM; EC50 = 7.4 μM), as determined in radioligand binding and electrophysiological experiments, respectively. The AMPA analogues 8a-c, containing 2-, 3-, or 4-methoxyphenyl substituents, respectively, and the corresponding hydroxyphenyl analogues, 9a-c, were also synthesized and evaluated pharmacologically. With the exception of 2-amino-3-[3-hydroxy-5-(2-hydroxyphenyl)-4-isoxazolyl]propionic acid (9a), which is a very weak AMPA agonist (IC50 = 45 μM; EC50 = 324 μM), none of these compounds showed detectable effect at AMPA receptors.